TREATMENT OF CD20-POSITIVE B-CELL LYMPHOMA WITH OBITUZUMABThe present disclosure relates to administration speed of obinutuzumab.Michael WENGERMehrdad MOBASHERChin-Yu LIN
of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma[...
4. Bannerji R, Arnason JE, Advani RH, et al. Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20 positive B-cell malignancies (ELM-1): results from the Relapsed or Refractory Non Hodgkin Lymphoma Cohort ...
8.Bannerji R, Arnason JE, Advani RH, et al. Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma ...
Reactivation of hepatitis B virus (HBV) after rituximab-containing chemotherapy in patients with B-cell lymphoma has been recognized as a potentially serious complication in HBV immune patients. 关键词: hepatitis B virus reactivation B-cell lymphoma rituximab antibody to hepatitis B core antigen 年份...
Ofatumumab (OFA, trade name Arzerra) is a fully human CD20-specific antibody that is active against CD20-positive B-cell lymphoma/chronic lymphocytic leukemia cells. In order to further enhance the anticancer effect of OFA, anti-CD20 OFA has been conjugated with highly cytotoxic monomethyl ...
[1] Shi, Yuankai,et al."Comparison of efficacy and safety of ripertamab (SCT400) versus rituximab (Mabthera®) in combination with CHOP in patients with previously untreated CD20‐positive diffuse large B‐cell lymphoma: A randomized, single‐blind, phase III clinical trial." Hematological ...
BackgroundThis study was designed to evaluate the safety and efficacy of a conventional dose of yttrium-90 (Y) ibritumomab tiuxetan combined with the etoposide rabinoside acytarabine melphalan (BEAM) regimen before autologous stem cell transplantation (ASCT) in chemosensitive relapsed or refractory low...
Rat B-cell leukemia/lymphoma 2,Bcl-2 免疫组化试剂盒 人白介素6(IL-6)免疫组化试剂盒 96T/48T Rat Caspase 3,Casp-3 免疫组化试剂盒 人白介素8(IL-8/CXCL8)免疫组化试剂盒 96T/48T Rat Orexin A 免疫组化试剂盒 人白介素9(IL-9)免疫组化试剂盒 96T/48T ...
【摘要】 CD20阴性弥漫性大B细胞淋巴瘤(diffuse large B- cell lymphoma,DLBCL)是一类罕见的异质性的淋巴增生性疾病。 CD20缺乏表达,细胞形态不典型,临床表现为侵袭性,以及对化疗耐药和低生存率为其特征,因此其治疗和诊断均是一个挑战。某科收治1例CD20阴性DLBCL患者,现报告如下,并进行相关文献复习。 Abstract 【...